Arvinas, Inc. 8-K Summary: Annual Meeting Results
Business Context and Reporting Period
This Form 8-K reports the results of the 2024 Annual Meeting of Stockholders held on May 29, 2024. Arvinas, Inc. is a biopharmaceutical company incorporated in Delaware, with its principal executive offices in New Haven, Connecticut.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
Stockholders voted on three primary proposals at the annual meeting:
- Director Elections (Class III): Three nominees were elected to the Board for terms expiring at the 2027 annual meeting.
- Everett Cunningham: 54,322,163 For; 3,128,381 Withheld.
- Edward Kennedy Jr.: 47,979,123 For; 9,471,421 Withheld.
- Briggs Morrison, M.D.: 38,515,137 For; 18,935,407 Withheld.
- Executive Compensation (Say-on-Pay): The non-binding advisory proposal was approved with 53,542,107 votes For and 3,886,277 votes Against.
- Independent Auditor Ratification: The appointment of Deloitte & Touche LLP for the fiscal year ending December 31, 2024, was ratified with 60,592,542 votes For and 123,004 votes Against.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting outcomes.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to contextualize the voting percentages.
- Confirm the specific terms and compensation packages for the newly elected Class III directors.
- Review the full proxy statement for details on the executive compensation plan approved by shareholders.
- Check subsequent filings for the company's financial performance, as this 8-K contains no financial data.